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OBJECTIVE: To analyze glucose transporter 1 expression patterns in malignant tumors of various cell types and
evaluate their diagnostic value by immunohistochemistry.
INTRODUCTION: Glucose is the major source of energy for cells, and glucose transporter 1 is the most common
glucose transporter in humans. Glucose transporter 1 is aberrantly expressed in several tumor types. Studies have
implicated glucose transporter 1 expression as a prognostic and diagnostic marker in tumors, primarily in
conjunction with positron emission tomography scan data.
METHODS: Immunohistochemistry for glucose transporter 1 was performed in tissue microarray slides, comprising
1955 samples of malignant neoplasm from different cell types.
RESULTS: Sarcomas, lymphomas, melanomas and hepatoblastomas did not express glucose transporter 1. Forty-
seven per cent of prostate adenocarcinomas were positive, as were 29% of thyroid, 10% of gastric and 5% of breast
adenocarcinomas. Thirty-six per cent of squamous cell carcinomas of the head and neck were positive, as were 42%
of uterine cervix squamous cell carcinomas. Glioblastomas and retinoblastomas showed membranous glucose
transporter 1 staining in 18.6% and 9.4% of all cases, respectively. Squamous cell carcinomas displayed membranous
expression, whereas adenocarcinomas showed cytoplasmic glucose transporter 1 expression.
CONCLUSION: Glucose transporter 1 showed variable expression in various tumor types. Its absence in sarcomas,
melanomas, hepatoblastomas and lymphomas suggests that other glucose transporters mediate the glycolytic
pathway in these tumors. The data suggest that glucose transporter 1 is a valuable immunohistochemical marker
that can be used to identify patients for evaluation by positron emission tomography scan. The function of
cytoplasmic glucose transporter 1 in adenocarcinomas must be further examined.
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INTRODUCTION
Glucose metabolism governs many functions, because the
oxidation of glucose generates a major source of metabolic
energy in eukaryotic cells.
1 Thus, glucose regulates tran-
scription, enzymatic activity, hormone secretion and the
activity of glucoregulatory neurons. These functions typi-
cally are secondary to glucose uptake, which is controlled
primarily by the glucose transporter family (GLUT 1–14).
2
Facilitative glucose transporters in the plasma membrane
mediate the flux of glucose between the extra- and
intracellular enviroments;
3 their expression and kinetic
and regulatory activities can be influenced by oncogenes
and growth factors.
4
The transport of glucose and other sugars is effected by a
gradient between the external and internal faces of the
plasma membrane.
5 Glucose uptake in nearly all cells is
mediated by GLUTs.
2,3
After glucose enters normal cells, it is converted into
pyruvate through glycolysis. Subsequently, pyruvate is
transformed into acetyl-CoA, which is used as substrate in
mitochondria to generate ATP.
6 In contrast, aerobic glyco-
lysis occurs in tumor cells—known as the Warburg effect—
7
also involving glucose transporter expression.
8 Hypoxia is a
hallmark of cancer, upregulating GLUT expression.
9
The GLUT family is expressed in the membrane of nearly
all cell types;
10 GLUT isoforms have tissue-specific expres-
sion patterns. There are 14 GLUT members,
11 of which
GLUT1, the first member of the GLUT family to be
identified, has been the most extensively studied.
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965GLUT1 was reported originally as a marker of infantile
skin hemangioma;
12 other vascular tumors and malforma-
tions do not express GLUT1 as robustly or ubiquitously.
13
Some groups have proposed the use of GLUT1 as a
diagnostic marker for hemangiomas in various locations.
12-15
GLUT1 is overexpressed in many tumors, including
hepatic, pancreatic, breast, esophageal, brain, renal, lung,
cutaneous, colorectal, endometrial, ovarian and cervical
cancers.
16-25 Conversely, immunohistochemistry shows that
GLUT1 expression is absent from certain human cancers.
Further, GLUT1 positivity in malignant cells revealed by
immunohistochemistry indicates increased proliferative
activity, energy requirements and aggressive behavior.
26,27
Increases in glucose consumption help supply the energy
that is necessary for tumor cell proliferation and reflect
adaptation to the adverse conditions of the tumoral
environment. Thus, metabolic changes have prognostic
and diagnostic value.
28 Although the metabolic conse-
quences of increased glucose transport are not understood,
GLUT1 expression apparently has significant clinical func-
tion in several tumors.
Currently, positron emission tomography (PET) scans are
performed to evaluate glucose uptake by cancer cells.
18F-
fluorodeoxyglucose is a glucose analog that is used in PET
to determine the anatomical and metabolic properties of
tumors.
29,30 Thus, enhanced glycolysis of tumor cells can be
detected, which is valuable in the diagnosis, staging,
assessments of recurrence and response to therapy of many
malignancies.
30,31 Tumors that express low levels of GLUT1,
however, pose a challenge for evaluations by PET scan.
This study was performed to measure GLUT1 immu-
noexpression in 1955 samples of malignant tumors of
various origins and locations and to evaluate its diagnostic
value by immunohistochemistry.
MATERIALS AND METHODS
Patients
We obtained 1955 cases of malignant tumor from the
archives of the Department of Anatomic Pathology,
Hospital A.C. Camargo, Sao Paulo, Brazil. The primary
sites, histological types and the number of samples
evaluated are shown in Table 1.
This experimental research was approved by the ethics
committee of our institution.
Tissue Microarray
The cases were reviewed and selected based on the
evaluations of 2 pathologists. Representative areas were
obtained in 2 cores (2 mm each) for each tumor. The original
blocks were retrieved from the hospital archives and used to
construct the tissue microarrays (TMAs). The TMA blocks
were sectioned onto coated slides (Starfrost, Lowestoft,
UKH) at a thickness of 4 mm using adhesive tape for
subsequent UV crosslinking (Instrumedics IncH, Hac-
kensack, NJ, USA), dipped in a layer of paraffin to prevent
oxidation and stored at 220˚C. One section was stained with
hematoxylin and eosin to evaluate the morphology of each
spot and the remaining slides were used in the immuno-
histochemistry study.
Immunohistochemistry
The sections were immunostained for GLUT1 using a
polyclonal antibody and the Advance polymeric visualiza-
tion system (DAKO, CA, USA). Two slides from the same
TMA block, separated by 40 sections, were stained.
The sections were dewaxed, rehydrated and antigens
retrieved into citrate buffer, pH 6.0, for 15 minutes in a
pressure cooker (Pascal, Dako). After being cooled at room
temperature and washed in water for 5 minutes, the sections
were quenched in H202 to block endogenous peroxidase
activity, followed by protein block for 20 minutes.
The primary antibody was applied for 2 hours at room
temperature and the stains were visualized with 3,39-
diaminobenzidine tetrachloride for 5 minutes. The slides
were counterstained lightly with hematoxylin, dehydrated
in ethanol and xylene and mounted with cover slips using
permanent mounting medium. In negative control slides,
the primary antibody was nonimmune IgG, with erythro-
cytes, which were present in every section, serving as
internal controls. All immunohistochemical reactions were
performed in duplicate.
Semiquantitative analysis was performed, as previously
described,
30,32,33 wherein tumors with up to 10% of cells
stained were considered to be negative and those with more
than 10% were positive.
RESULTS
GLUT1 expression patterns varied between malignant
tumor samples (Figure 1 and Table 1). Sarcomas, lympho-
mas, melanomas and hepatoblastomas did not express
GLUT1 (Figure 2 and Table 1). However, in adenocarci-
noma, cytoplasmic and diffuse patterns of staining were
observed concomitantly with membranous staining
(Figure 3).
In 195 prostate tumors, the proportion of GLUT1-
positive:GLUT1-negative tumors was 925103 (47% positive),
25560 in 85 cases of thyroid tumor (29% positive cases, 35%
of which were papillary and 19% follicular tumors), 385339
in 377 gastric tumor samples (10% positive, 17% of which
were intestinal and 14% diffuse tumors) and 135254 in 267
breast tumor cases (5% positive) (Figure 3). Tables 1 and 2
summarise the immunohistochemistry results.
Table 1 - Samples evaluated by immunohistochemistry.
Primary site, histological type and number (percentage)
of positive and negative samples are indicated.
Tumor GLUT1-stained samples
Positive
n (%)
Negative
n (%)
Total
number
of cases
Prostate 92 (47) 103 (53) 195
Thyroid 25 (29) Papillary (35%) 60 (71) 85
Follicular (19%)
Gastric 38 (10) Intestine (17%) 339 (90) 377
Diffuse (4%)
Breast 13 (5) 254 (95) 267
Head and neck 62 (36) 110 (64) 172
Cervix uterine 69 (42) 95 (58) 164
Glioblastomas 16 (18.6) 70 (81.4) 86
Retinoblastomas 12 (9.4) 116 (90.6) 128
Lymphomas 0 297 (100) 297
Sarcomas 0 97 (100) 97
Melanomas 0 67 (100) 67
Hepatoblastomas 0 20 (100) 20
Total number 327 1628 1955
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966Conversely, squamous cell carcinomas expressed GLUT1
exclusively in the membrane. In 172 cases of head and neck
tumors, the proportion of GLUT1-positive:GLUT1-negative
cases was 625110 (36% positive) compared with 69595 in 164
cervix uterine samples (42% positive) (Figure 3).
Glioblastoma and retinoblastoma samples showed mem-
branous GLUT1 expression in 16 of 86 cases and 12 of 128
(18.6% and 9.4% positive cases), respectively.
DISCUSSION
Glucose transporters, such as GLUT1, mediate basal
glucose transport in cancer cells, regulating the maintenance
of energy metabolism in the cells located in limited supply
tissue regions.
34 Hypoxia (low tissue oxygen pressure) is a
hallmark of various cancers and is often associated with
disease progression. That process occurs when tumors
outgrow the existing vasculature. Thus, tumors respond to
hypoxic conditions by activating genes that regulate
glycolysis and glucose transport.
35
Malignant cells require high energy levels via glycolytic
generation of ATP to proliferate and survive. In cancer-
induced starvation, GLUT1 overexpression governs
mechanisms that favor tumor growth at the expense of
host tissues.
36,37 Thus, we examined GLUT1 expression,
because higher levels of GLUT1 in cancer indicate a poor
prognosis.
38,39
This study performed a novel examination of GLUT1
expression in several tumor types. GLUT1 expression and
its function have not been previously reported in most of the
tumors that we examined. We analyzed several primary
sites and histological types of tumors (1955 tumors of 12
histological types; see Table 1 for reference) and observed
that GLUT1 expression varied between tumor types. GLUT1
was evaluated by immunohistochemistry using a standar-
dized scale, which considers tumors in which more than
10% of cells per field are stained to be positive.
30-33
The patterns of GLUT1 expression in adenocarcinomas
and squamous cell carcinomas differed in location and
frequency in tumor cell compartments. Prostate, breast,
gastric and thyroid adenocarcinomas showed cytoplasmic
expression with varying intensities. The highest frequency
of GLUT1 expression was observed in prostate (47%) and
thyroid tumors (29%).
Some groups evaluated GLUT expression in human
prostate cancer, noting GLUT1 and GLUT12 mRNA and
protein expression.
40 Also, they observed membranous and
cytosolic GLUT1 and GLUT12 expression in prostate
carcinoma cell lines, demonstrating GLUT1 colocalization
with the Golgi.
Recently, Jans et al.
41 suggested that cytoplasmic GLUT1
expression is an important prognostic factor. They showed
that patients with elevated levels of GLUT1 have signifi-
cantly shorter times before biochemical recurrence after
radical prostectomy. Nevertheless, it is unknown whether
elevated GLUT1 expression accurately reflects the hypoxic
state of the tumor (the hypoxic state influences disease
progression) or whether elevated GLUT1 levels are an
indication of the altered metabolic state of tumor cells.
Regardless, cytoplasmic GLUT1 expression can be used as a
prognostic marker in prostate cancer.
40,42
Our prostate adenocarcinoma samples showed robust
cytoplasmic GLUT1 expression, consistent with other
reports. But, the significance of cytoplasmic GLUT1 expres-
sion in several tumors is unknown, because it is active as a
transporter only in the cell membrane. Recently, Taganaka
and Frommer
43 examined whether glucose transporters that
are destined for the plasma membrane are active during
endoplasmic reticulum transit, concluding that GLUTs
mediate endoplasmic reticulum glucose transport en route
to the plasma membrane.
We grouped thyroid adenocarcinoma cases into 2
subtypes—papillary (35% positivity) and follicular (19%
positivity)—both of which showed GLUT1 cytoplasmic
Figure 1 - Profile of GLUT1 expression by histological tumor type. The graph shows the percentage of GLUT1-positive (POS) and -negative
(NEG) samples determined by immunohistochemistry.
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967expression. Similarly, a study
44 analyzed 268 cases of
thyroid carcinoma by immunohistochemistry and observed
that papillary carcinoma cells had membranous staining
patterns (19%) and some cytoplasmic staining (52%).
Moreover, they noted GLUT1 expression in 5% of follicular
carcinomas but that all follicular adenomas and adenoma-
tous goiters were negative. Their results suggest that GLUT1
can be used to distinguish papillary and follicular carcino-
mas and benign diseases. Also, GLUT1 might aid the
determination of papillary carcinoma and lymph node
metastasis; its membranous expression appears to have
greater clinical value than its cytoplasmic expression.
44
Another study
45 analyzed the expression of several GLUT
isoforms in tumor cell lines from anaplastic, papillary,
follicular and medullary human thyroid carcinomas.
GLUT1 mRNA was expressed in malignant tissues and
was the most prevalent isoform in less-differentiated cells.
45
Ten per cent of gastric tumors (including intestinal and
diffuse tumors) are positive for GLUT1, generating cyto-
plasmic patterns. In 2001, Kawamura et al.
46 evaluated 667
gastric tumors (including 50 tubular gastric adenomas and
617 gastric carcinomas) by immunohistochemistry and
showed that 182 gastric carcinomas, but none of the tubular
gastric adenomas, expressed GLUT1. Moreover, in an
analysis of clinicopathological characteristics, GLUT1 was
expressed late in carcinogenesis, increasing with disease
progression. The authors considered only membrane-spe-
cific reactions to be positive.
46
Subsequently, Wei et al.
47 examined GLUT1 expression in
gastric carcinomas and observed a stronger correlation
between expression and clinical parameters, suggesting that
GLUT1 is a prognostic factor. In our study, we evaluated
many samples and noted robust cytoplasmic staining and,
additionally, some gastric tumors showed membranous
staining. Both membrane and cytoplasmic staining patterns
were considered to be positive in our analysis.
GLUT expression
48-54 has been correlated to tumor grade
in breast cancer.
54,55 Hao et al.
56 linked GLUT1 over-
expression and progression of breast carcinoma. However,
GLUT1 is absent in fibroadenoma and hyperplastic lesions,
suggesting it as a target for treatment. Groves et al.
57
examined the correlation between
18F-FDG uptake and
GLUT1 or CD105 expression in 20 patients with early breast
cancer, observing a poor association. A stronger correlation
was noted between CD105, a marker of angiogenesis, and
PET results in patients with early breast cancer. No
significance was observed in GLUT1 analysis. In our
experiments, only 5% of breast tumors (13/254 samples)
expressed GLUT1.
Because we did not assess the clinical characteristics of
our patients, we could not determine whether the smaller
number of GLUT1-expressing samples was due to varia-
tions in disease status and development. Also, several
compounds have been reported to regulate glucose trans-
porter expression in breast cancer, such as hypoxia,
estradiol and epidermal growth factor.
7
Polymorphisms in GLUT1 have also been considered as a
regulator of expression. Grabellus et al.
58 analyzed 3 GLUT1
polymorphisms and observed increased glucose uptake in
samples that harbored the XbaI G.T single nucleotide
Figure 2 - Absence of GLUT1 expression. A, sarcoma sample; B, lymphoma; C, melanoma; D, hepatoblastoma.
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968polymorphism by PET. They did not assess GLUT1 levels but
noted that GLUT1 polymorphisms interfered with glucose
uptake in tumors. However, the variability in GLUT1
expression in breast tumor must be further examined.
In general, we observed adenocarcinomas with cytoplas-
mic GLUT1 expression (with or without continuous staining
of the membrane). This expression profile has not pre-
viously been described in tumors, necessitating further
investigation of its effects on tumor behavior and biology.
Head and neck (36%) and cervix uterine squamous cell
carcinomas (42%) showed significant membranous staining
in our samples. GLUT1 function in squamous cell carcinoma
biology and behavior is being examined by our group.
Invariably, GLUT1 is overexpressed in head and neck
tumors. Similarly, Baer et al.
59 noted consistent overexpres-
sion of GLUT1 (100%) in 48 biopsy specimens from patients
with laryngeal invasive carcinoma; this expression does not
influence survival rates.
GLUT1 is highly expressed in squamous cell carcinomas
of the head and neck (HNSCCs).
60 That GLUT1 expression
increases in dysplastic lesions and sustains its expression in
squamous cell carcinoma indicates that changes in GLUT1
levels represent early events during the development of
HNSCCs. The study authors concluded that GLUT1 is a
reliable marker in the diagnosis of premalignant lesions of
the oropharyngeal mucosa. Recently, we demonstrated that
higher GLUT1 expression in oral squamous cell carcinoma
is associated with poor prognosis.
61
Figure 3 - Cytoplasmic GLUT1 expression in adenocarcinomas and membrane expression in squamous cell carcinomas. A, prostate
tumor; B, papillary thyroid tumor; C, gastric tumor; D, breast tumor; E, squamous cell carcinoma of uterine cervix; F, squamous cell
carcinoma of the head and neck.
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969Few studies have examined GLUT expression in melano-
mas, lymphomas, sarcomas and hepatoblastomas, and some
of these concluded that GLUT1 levels in melanoma samples
by immunoblotting contribute to variability in the responses
of these tumors to treatment.
62
GLUT1 is also expressed in sarcomas, detected in 50% of
intrauterine leiomyosarcomas and 25% of extrauterine
sarcomas by immunohistochemistry. GLUT1 positivity
correlates closely with aggressive biological behavior,
reflected by distant metastatic spread.
63 Our samples
comprised a wide and heterogeneous group of sarcomas,
but we failed to detect GLUT1 in any of these cases.
There was no detectable expression of GLUT1 in our
sarcoma, melanoma, hepatoblastoma or lymphoma sam-
ples, which suggests that another glucose transporter
maintains glycolytic metabolism in these tumors or that
GLUT1 is expressed at specific stages of carcinogenesis.
Lymphomas might be such an example. These tumors rarely
express GLUT1 but frequently express GLUT3. Recent
studies with PET have shown that primarily T-cell
lymphomas and indolent malignant lymphomas have lower
metabolic activity.
64,65 Our group examined GLUT3 expres-
sion in non-Hodgkin lymphoma samples, observing higher
levels in tumor cells (data not shown). Also, some studies
have shown that prostate adenocarcinomas preferentially
express GLUT12, in association with lower levels of
GLUT1.
66
We cannot reject the hypothesis that inhibitory elements
block GLUT1 protein, such as post-transcriptional regula-
tory factors, GLUT1 polymorphisms and epigenetic events.
Nevertheless, GLUT1 can be a useful marker for the
differential diagnosis of negative tumors and others.
To this end, PET scans are useful in determining the
prognosis of several tumors, as described for breast,
lymphomas, thyroid, oral squamous cell carcinomas and
other cancers,
33,41,56,58,67 providing anatomical and meta-
bolic data on tumors. PET scans have provided indirect
evidence about the function of GLUT1 in carcinogenesis,
and several studies have correlated glucose analog (
18-F-
FDG) uptake and tumor aggressiveness.
68-70 Thus, this
technique demonstrates the value of
18-F-FDG as a prog-
nostic factor for hepatocarcinomas, breast and colorectal
cancers, thymic epithelial tumors and other cancers.
Tumors that express little or no GLUT1 may pose a
challenge for PET scan analysis—for example, when tumors
express another glucose transporter that cannot be recog-
nized or does not have affinity for
18-F-FDG. Our results
suggest that immunohistochemical staining of GLUT1 can
identify patients for evaluation by PET.
Similarly to other reports, our results demonstrate
variable GLUT1 expression in different tumor types. Yet,
we believe that its absence in sarcomas, melanomas,
hepatoblastomas and lymphomas suggests that other
glucose transporters regulate the glycolytic pathway in
these tumors. The true function of cytoplasmic GLUT1 in
adenocarcinomas must be examined further.
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